Sanofi wraps up Acambis deal; AstraZeneca prevails in Pulmicort suit

> Sanofi-Aventis is set to complete its acquisition of Britain's Acambis today, with plans to keep the vaccine developer partly autonomous, to maintain its entrepreneurial spirit. Report

> AstraZeneca won a U.S. court ruling against Teva Pharmaceutical Industries that upholds patent protection on the children’s version of the Pulmicort asthma treatment. Report

> Boston Scientific got the FDA nod for its new Taxus Express2 drug-coated stent, the only stent approved for small blood vessels. Report

> PDL BioPharma named Faheem Hasnain president and chief executive, and said he will take that role in its spin-off company, Facet Biotech Corp. PDL release

> Oriel Therapeutics has named Dr. Richard Fuller as CEO; most recently he was executive vice president of Aerovance. Report

> Seniors who switch between low-cost generic drugs and the original products based on who's footing the bill are likely driving up the cost of the government's Medicare drug plan, according to a new study. Report

> ForteBio is pocketing $25 million from its third round of venture capital. OrbiMed Advisors led the round with MPM Capital, Alloy Ventures, Versant Ventures, The Vertical Group and Latterell Venture Partners joining in. Report

> Sequenom won $20 million in grants from the state of Michigan as it completes a deal to buy a lab in Grand Rapids and expand the operations, bringing more than 500 new jobs to the economically depressed region. Report

> An international study from Canada's McGill University says that the aggressive patent strategies of the world's biotech and pharma companies--as well as universities--are stifling innovation. Report

> A small mid-stage study has produced positive interim data for Cytokinetics' experimental drug CK-1827452. A full set of data will be delivered to Amgen--which has an option to co-develop the drug--by the end of the year. Report

> Although the study was previously halted by the FDA, Allergy Therapeutics says its Pollinex Quattro ragweed vaccine met its primary endpoint, demonstrating a statistically significant response. The company plans to go ahead and pursue an approval in Canada. Report

And Finally... Big Pharma's top 13 advertising budgets. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.